Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex in Subjects With Ataxia Telangiectasia (NEAT)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 02 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Nov 2025 According to a Quince Therapeutics media release, the company announced the positive outcome of its pre-planned safety analysis conducted by an independent data and safety monitoring board (iDSMB) for this study. The iDSMB recommended that the study continue without any modifications.
09 Oct 2025 According to a Quince Therapeutics media release, the data from the trial was presented at the 54th Child Neurology Society (CNS) Annual Meeting.
11 Sep 2025 According to a Quince Therapeutics media release, today announced that it will host a virtual Investor Day on Thursday, October 2, 2025, from 10:00 a.m. and 12:00 p.m. Eastern Time, and share updates (regulatory overview) from this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com